Treatment rechallenge after trastuzumab-deruxtecan–related interstitial lung disease: A multi-institution cohort study. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This ...
NEW YORK, NY, UNITED STATES, January 16, 2026 /EINPresswire.com/ — OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world ...
In the long and often dispiriting quest to cure cancer, the 1998 approval of the drug Herceptin was a tremendously hopeful moment. This drug for breast cancer was the first to use a tumor-specific ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results